Akkade Bioscience

Akkade Bioscience is a biotechnology company dedicated to the development of innovative mRNA-based therapeutics and vaccines. The company leverages its proprietary lipid nanoparticle (LNP) delivery platform, which is engineered to achieve superior tissue-specific targeting, particularly for extra-hepatic applications. Akkade's research focus spans infectious diseases, oncology, and protein replacement therapies for rare genetic disorders. Headquartered in Suzhou, China, the company is supported by prominent investors including Matrix Partners China and Sherpa Healthcare Partners. Akkade Bioscience aims to overcome the delivery challenges of RNA medicines to provide transformative treatments for patients worldwide.